AXSM - Axsome Therapeutics Inc

https://www.axsome.com

Buy Momentum: Bearish

Recent News

Axsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings - Axsome Therapeutics ( NASDAQ:AXSM )

Benzinga • 1 month, 1 week ago • score: 0.32

Axsome Therapeutics, Inc. AXSM reported better-than-expected second-quarter financial results on Monday. Axsome Therapeutics reported quarterly losses of 47 cents per share compared to analyst consensus estimate of losses of $1.07 per share.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

Axsome Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new therapies for central nervous system (CNS) disorders in the United States. The company is headquartered in New York, New York.

52W High

$139.13

52W Low

$75.56

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

0.53

Valuation

Rich

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

384.62

EV/EBITDA (<8 favorable)

-14.81

EV/Revenue (<3 favorable)

12.44

P/S (TTM) (<3 favorable)

12.62

P/B (<3 favorable)

85.48

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

15.87%

Institutions (25–75% balanced)

77.49%

Shares Outstanding

49,901,500

Float

41,983,100

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

495,033,000

Gross Profit (TTM)

452,845,000

EPS (TTM)

-5.06

Profit Margin (>10% good)

-0.50%

Operating Margin (TTM) (higher better)

-0.30%

ROE (TTM) (>15% strong)

-2.81%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.72

Momentum

Bearish momentum

Value

4.2312

5.1367

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025